RÉSUMÉ
BACKGROUND AND OBJECTIVE: One of the main goals of epidemiological studies is to build models capable of forecasting the prevalence of a contagious disease, in order to propose public health policies for combating its propagation. Here, the aim is to evaluate the influence of immune individuals in the processes of contagion and recovery from varicella. This influence is usually neglected. METHODS: An epidemic model based on probabilistic cellular automaton is introduced. By using a genetic algorithm, the values of three parameters of this model are determined from data of prevalence of varicella in Belgium and Italy, in a pre-vaccination period. RESULTS: This methodology can predict the varicella prevalence (with average relative error of 2%-4%) in these two European countries. Belgium data can be explained by ignoring the role of immune individuals in the infection propagation; however, Italy data can be explained by considering contagion exclusively mediated by immune individuals. CONCLUSIONS: The role of immune individuals should be accurately delineated in investigations on the dynamics of disease propagation. In addition, the proposed methodology can be adapted for evaluating, for instance, the role of asymptomatic carriers in the novel coronavirus spread.
Sujet(s)
Immunité acquise/immunologie , Infection à virus varicelle-zona/épidémiologie , Algorithmes , Belgique/épidémiologie , Herpèsvirus humain de type 3/génétique , Humains , Italie/épidémiologie , Modèles théoriques , Mutation , Prévalence , Probabilité , Reproductibilité des résultats , Logiciel , Infection à virus varicelle-zona/transmissionRÉSUMÉ
BACKGROUND: This study was designed to determine the debated prognostic significance of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity in melanoma patients' sentinel lymph node (SLN) negative by conventional histopathology (PATH). PATIENTS AND METHODS: Patients with primary stage I-II cutaneous melanoma underwent radioguided sentinel lymphadenectomy. Their SLNs were assessed for tyrosinase (Tyr) and melanoma antigens recognized by T-cells (MART-1) mRNA expression using RT-PCR, in parallel with hematoxylin and eosin staining and immunohistochemistry. Tyr and MART-1 expression in the SLNs were correlated with PATH assay results, standard prognostic factors, time to progression and overall survival. RESULTS: Twenty-three of the 124 patients (18.5%) had positive SLNs by both PATH and RT-PCR (PATH+/PCR+). Sixteen patients (13%) were negative by PATH and positive by RT-PCR (PATH-/PCR+). Eighty-five patients (68.5%) had SLNs that were negative by both PATH and RT-PCR (PATH-/PCR-). At a median follow-up of 30 months, recurrence rates among the three cohorts were statistically different (PATH+/PCR+, 60%; PATH-/PCR+, 31%; PATH-/PCR-, 9.4%). Seven of 23 (30%) and two of 16 (12.5%) patients died in the PATH+/PCR+ and PATH-/PCR+ SLN groups, respectively, whereas no patient died in the PATH-/PCR- SLN group. CONCLUSIONS: RT-PCR is more sensitive than PATH to detect SLN metastases and it is a reliable predictor of disease relapse in stage I-II melanoma patients.
Sujet(s)
Mélanome/anatomopathologie , Monophenol monooxygenase/génétique , Protéines tumorales/génétique , Biopsie de noeud lymphatique sentinelle , Tumeurs cutanées/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antigènes néoplasiques , Études de cohortes , Évolution de la maladie , Femelle , Études de suivi , Tumeurs de la tête et du cou/traitement médicamenteux , Tumeurs de la tête et du cou/génétique , Tumeurs de la tête et du cou/anatomopathologie , Humains , Lymphadénectomie , Antigène MART-1 , Mâle , Mélanome/traitement médicamenteux , Mélanome/génétique , Adulte d'âge moyen , Récidive tumorale locale/traitement médicamenteux , Récidive tumorale locale/génétique , Récidive tumorale locale/anatomopathologie , Stadification tumorale , Pronostic , ARN messager/génétique , ARN messager/métabolisme , RT-PCR , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/génétique , Taux de survie , Facteurs tempsRÉSUMÉ
HTIF1alpha, a transcription coactivator which is able to mediate RARalpha activity and functionally interact with PML, is encoded by a gene on chromosome 7q32-34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may be related to AML, we investigated the HTIF1alpha DNA structure and RNA expression in leukemic cells from 36 M1-M5 AML patients (28 "de novo" and eight "secondary" to myelodysplastic syndrome (MDS)). Abnormal HTIF1alpha DNA fragments were never found, whereas loss of HTIF1alpha DNA was observed in the patients with chromosome 7q32 deletion and translocation, and in one case without detectable chromosome 7 abnormality. HTIF1alpha RNA was found in acute myelocytic leukemic blasts, and was almost undetectable in normal mononuclear cells. The expression varied among the patients: higher in M1 to M3 subtypes, with the highest values in M1; low levels were constantly observed in M4 and M5 AML. In addition, HTIF1alpha was significantly overexpressed in MDS-related AML (MDR-AML), but not in MDS. We also found that HTIF1alpha expression was high in myeloid cell lines. In myeloblastic HL60 and promyelocytic NB4 cells, induced to differentiate along the monocytic-macrophage pathway by TPA or vitamin D3, HTIF1alpha expression decreased, whereas it was maintained at high levels on induction to granulocytic differentiation by RA or DMSO. In K562 cells, HTIF1alpha RNA levels did not change after hemin-induced erythroid differentiation. These results suggest that HTIF1alpha could play a role in myeloid differentiation, being distinctly regulated in hematopoietic lineages.
Sujet(s)
Régulation de l'expression des gènes , Leucémie myéloïde/génétique , Syndromes myélodysplasiques/génétique , Protéines nucléaires/génétique , Facteurs de transcription/génétique , Maladie aigüe , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Cellules sanguines/anatomopathologie , Moelle osseuse/anatomopathologie , Études cas-témoins , Différenciation cellulaire , Aberrations des chromosomes , Chromosomes humains de la paire 7/génétique , ADN/composition chimique , Femelle , Humains , Leucémie myéloïde/classification , Leucémie myéloïde/étiologie , Mâle , Adulte d'âge moyen , Protéines nucléaires/physiologie , Isoformes de protéines/génétique , ARN messager/métabolisme , Facteurs de transcription/physiologie , Cellules cancéreuses en cultureSujet(s)
Protéines de fusion bcr-abl/génétique , Thrombocytémie essentielle/génétique , Maladie aigüe , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Italie/épidémiologie , Leucémie myéloïde/génétique , Mâle , Adulte d'âge moyen , Chromosome Philadelphie , RT-PCR , Sensibilité et spécificité , Thrombocytémie essentielle/sang , Thrombocytémie essentielle/épidémiologieRÉSUMÉ
The presence of lymph node metastases is the best prognostic factor for predicting relapse or survival in melanoma patients. It has been demonstrated that melanoma metastases spread through the first lymph node(s) draining the tumor (sentinel lymph node, SN) to the lymphatic system and that detection of melanoma cells in peripheral blood directly correlates with prognosis in melanoma. To identify lymph node metastases and circulating melanocytes, we developed a single-step reverse transcriptase-polymerase chain reaction assay (RT-PCR) for detection of two melanoma-specific markers: the tyrosinase gene, which encodes an enzyme associated with melanin synthesis, and melanoma antigen-related T-cells, which are present in tumor infiltrating T-lymphocytes. This method detects two tumor cells in a background of 10(7) lymphocytes. Thirty patients with stage I-IV cutaneous melanoma entered the study. Blood samples were taken preoperatively, one month after excision of the primary melanoma lesion and the SN or total lymphadenectomy, and before the start of chemotherapy and every three months thereafter in metastatic patients. SNs were collected from 22 patients, bisected and analyzed by RT-PCR and routine pathological and immunohistochemical tests. The preliminary results indicate that RT-PCR for melanoma markers is a sensitive and valuable method for the detection of micrometastases and for early diagnosis and staging of melanoma.
Sujet(s)
Antigènes néoplasiques/génétique , Noeuds lymphatiques/anatomopathologie , Mélanome/anatomopathologie , Monophenol monooxygenase/génétique , ARN tumoral/analyse , RT-PCR , Biopsie de noeud lymphatique sentinelle , Tumeurs cutanées/anatomopathologie , Lymphocytes T/anatomopathologie , Adulte , Sujet âgé , Femelle , Humains , Noeuds lymphatiques/imagerie diagnostique , Noeuds lymphatiques/enzymologie , Noeuds lymphatiques/immunologie , Mâle , Mélanome/sang , Mélanome/imagerie diagnostique , Mélanome/enzymologie , Mélanome/génétique , Mélanome/immunologie , Adulte d'âge moyen , Scintigraphie , Radiopharmaceutiques , Biopsie de noeud lymphatique sentinelle/méthodes , Tumeurs cutanées/sang , Tumeurs cutanées/imagerie diagnostique , Tumeurs cutanées/enzymologie , Tumeurs cutanées/génétique , Tumeurs cutanées/immunologie , Agrégat d'albumine marquée au technétium (99mTc)RÉSUMÉ
BACKGROUND AND OBJECTIVES: The translocation t(11;14) (q13;q32), typically described in mantle cell lymphomas (MCL), has also been found in some cases of non-MCL lymphoproliferative disorders, such as splenic lymphoma with villous lymphocytes (SLVL), multiple myeloma (MM), prolymphocytic leukemia (PLL), typical and atypical chronic lymphocytic leukemia (CLL and aCLL). In order to define better the genetic features of aCLL with t(11;14), which could represent a distinct disease subset, we looked for genetic lesions in the BCL-1 locus and in BCL-2, BCL-6, c-myc and p53 genes. DESIGN AND METHODS: We investigated a panel of B-lymphoproliferative disorders with translocation t(11;14)(q13;q32) including nine aCLL, six MCL and one MM. Southern and Northern blot analysis was used to investigate DNA structure and RNA expression; SSCP and direct sequencing were used to detect and characterize p53 point mutations; cytofluorimetric analysis was used to quantify p53 protein. RESULTS: Alterations of BCL-2, BCL-6 and c-myc were not detected. Conversely, BCL-1 rearrangements were present in 4 out of 7 aCLL and in 2 out of 4 MCL. A high incidence of p53 gene alterations was found, almost equivalent in aCLL and MCL. INTERPRETATION AND CONCLUSIONS: Our results indicate that the occurrence of BCL-1 locus lesions in aCLL selected for t(11;14) is as high as in MCL. Interestingly, rearrangements in the mTC1 (minor translocation cluster 1) were only found in aCLL. Therefore, the two B-cell chronic lymphoproliferative disorders share similar molecular rearrangements and the t(11;14) identifies a subset of B-CLL sharing molecular features with MCL and characterized by aggressive clinical evolution.
Sujet(s)
Chromosomes humains de la paire 11 , Chromosomes humains de la paire 14 , Gènes bcl-1 , Leucémie chronique lymphocytaire à cellules B/génétique , Mutation , Translocation génétique , Protéine p53 suppresseur de tumeur/génétique , Adulte , Sujet âgé , Lymphocytes B/immunologie , Lymphocytes B/métabolisme , Analyse cytogénétique , Femelle , Réarrangement des gènes , Humains , Immunophénotypage , Lymphome à cellules du manteau/génétique , Mâle , Adulte d'âge moyen , Myélome multiple/génétiqueRÉSUMÉ
PML and Tif1a are fused to RARA and Braf, respectively, resulting in the production of PML-RARalpha and Tif1alpha-B-Raf (T18) oncoproteins. Here we show that PML, Tif1alpha and RXRalpha/RARalpha function together in a transcription complex that is dependent on retinoic acid (RA). We found that PML acts as a ligand-dependent coactivator of RXRalpha/RARalpha. PML interacts with Tif1alpha and CBP. In Pml-/- cells, the RA-dependent induction of genes such as RARB2 and the ability of Tif1alpha and CBP to act as transcriptional coactivators on RA are impaired. We show that both PML and Tif1alpha are growth suppressors required for the growth-inhibitory activity of RA. T18, similar to PML-RARalpha, disrupts the RA-dependent activity of this complex in a dominant-negative manner resulting in a growth advantage. Our data define a new pathway for the control of cell growth and tumorigenesis, and provide a new model for the pathogenesis of acute promyelocytic leukaemia (APL).
Sujet(s)
Régulation de l'expression des gènes tumoraux , Leucémie aiguë promyélocytaire/génétique , Protéines tumorales/métabolisme , Protéines nucléaires/métabolisme , Protéines de fusion oncogènes/métabolisme , Récepteurs à l'acide rétinoïque/métabolisme , Facteurs de transcription/métabolisme , Trétinoïne/pharmacologie , Animaux , Protéine CBP , Différenciation cellulaire/effets des médicaments et des substances chimiques , Division cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire , Noyau de la cellule/métabolisme , Transformation cellulaire néoplasique/effets des médicaments et des substances chimiques , Transformation cellulaire néoplasique/génétique , Transformation cellulaire néoplasique/métabolisme , Transformation cellulaire néoplasique/anatomopathologie , ADN/génétique , ADN/métabolisme , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Gènes suppresseurs de tumeur/génétique , Gènes suppresseurs de tumeur/physiologie , Humains , Leucémie aiguë promyélocytaire/métabolisme , Leucémie aiguë promyélocytaire/anatomopathologie , Mutation , Protéines tumorales/composition chimique , Protéines tumorales/génétique , Protéines nucléaires/antagonistes et inhibiteurs , Protéines nucléaires/composition chimique , Protéines de fusion oncogènes/composition chimique , Protéines de fusion oncogènes/génétique , Régions promotrices (génétique)/génétique , Liaison aux protéines , Isoformes de protéines/génétique , Isoformes de protéines/métabolisme , Récepteurs à l'acide rétinoïque/génétique , Récepteurs X des rétinoïdes , Transactivateurs/métabolisme , Facteurs de transcription/antagonistes et inhibiteurs , Facteurs de transcription/composition chimique , Facteurs de transcription/génétique , Transfection , Trétinoïne/métabolismeRÉSUMÉ
Acute promyelocytic leukemia (APL) has been regarded as the paradigm for therapeutic approaches utilizing differentiating agents, due to the fact that almost 95% of patients undergo complete remission when treated with all-trans retinoic acid (ATRA). However, complete clinical remission with ATRA alone is always transient, and relapse in APL is almost invariably associated with the acquisition of resistance to ATRA. Acquired resistance to ATRA in APL cell lines and in some APL clinical cases can be partially overcome by interferons (IFNs), cytokines which have well established tumor-growth suppressive activities. APL is associated in 99% of cases with a 15;17 translocation that fuses the PML and Retinoic Acid Receptor alpha (RARalpha) genes. RARalpha is one of the Retinoic Acid (RA) nuclear receptors which mediates, at the transcriptional level, ATRA differentiating and growth suppressive activity. PML is a tumor-growth suppressor whose expression is directly regulated by IFNs. Here we review the molecular mechanisms by which IFNs and RA can cooperate in controlling cell growth and differentiation of normal hemopoietic cells and leukemic cells, focusing on APL as a model system.
Sujet(s)
Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Interférons/usage thérapeutique , Leucémie aiguë promyélocytaire/traitement médicamenteux , Modèles biologiques , Transduction du signal/effets des médicaments et des substances chimiques , Trétinoïne/usage thérapeutique , Synergie des médicaments , Humains , Induction de rémission/méthodesRÉSUMÉ
Acute Promyelocytic Leukemia (APL) is a distinct subtype of myeloid leukemia that in the USA alone affects more than 3,000 individuals every year. APL is characterized by three distinct and unique features: i) the accumulation in the bone marrow of tumor cells with promyelocytic features; ii) the invariable association with specific translocations which always involve chromosome 17 and the Retinoic Acid Receptor alpha (RAR alpha) locus; iii) the exquisite sensitivity of APL blasts to the differentiating action of Retinoic Acid (RA). These features have led APL to become the paradigm for therapeutic approaches utilizing differentiating agents. The last 5 years have provided crucial insights into the molecular basis of APL. RAR alpha translocates in 99% of cases to a gene located on chromosome 15 that we initially named myl and subsequently has been called PML. In a few cases, RAR alpha variably translocates to chromosome 11 where it fuses to the PLZF gene or to a newly described partner, NuMA. In addition, RAR alpha is also found translocated to chromosome 5 where it fuses to the NPM gene. The cloning of variant translocations in APL and the comparative analysis of their associated products is crucial for the understanding of the molecular etiopathogenesis of the disease. The generation of animal models, i.e., transgenic mice expressing the fusion genes, will be instrumental in determining the precise contribution of these fusion genes to leukemogenesis. In fact, mice harboring a PML/RAR alpha transgene whose expression is specifically targeted to the myeloid-promyelocytic lineage develop acute myeloid leukemia with promyelocytic features. Moreover, the functional analysis of the various fusion proteins, as well as RAR alpha partners, is revealing striking common features beneath a misleading structural heterogeneity which unravels a possible unifying molecular mechanism towards APL leukemogenesis.
Sujet(s)
Réarrangement des gènes , Leucémie aiguë promyélocytaire/génétique , Animaux , Division cellulaire/physiologie , Noyau de la cellule/physiologie , Gènes tumoraux , Gènes suppresseurs de tumeur/physiologie , Hématopoïèse/physiologie , Humains , Biologie moléculaireRÉSUMÉ
The laryngeal mask airway is a completely new concept in airway management and has the potential to provide a third airway option for the neonate. The device sits in the hypopharynx at the interface between the gastrointestinal and respiratory tracts, where it forms a circumferential low-pressure seal around the glottis. This article provides an overview of the laryngeal mask airway and focuses on its potential as a neonatal airway outside the operating room.
Sujet(s)
Masques laryngés , Soins infirmiers en néonatalogie , Anesthésiologie , Conception d'appareillage , Humains , Nouveau-né , Unités de soins intensifs néonatals , Transfert de patient , Réanimation/instrumentationRÉSUMÉ
The PML gene is fused to the retinoic acid receptor alpha gene (RAR alpha) in the acute promyelocytic leukemia (APL) 15; 17 translocation. PML is expressed in diverse tissues and cell lines and localized in the nucleus with a typical speckled pattern. In the bone marrow, it is preferentially expressed in myeloid cells. PML appears to be transcriptionally regulated by class I and II interferons, which raises the possibility that interferons modulate the function and growth and differentiation potential of normal myeloid cells and precursors by activating PML-dependent pathways. Similarly, interferons could act on APL cells, alone or in combination with all-trans retinoic acid (RA), especially if the PML/RAR alpha fusion transcript that results from the t(15; 17) is induced by interferon. We report here that PML is expressed at low levels or not expressed in normal circulating human monocytes, lymphocytes, and polymorphonucleate cells, but is markedly induced by interferon; that PML and PML/RAR alpha expression is augmented by interferon in the NB4 APL cell line, which carries the t(15; 17), and in APL blasts from patients; that interferon inhibits growth and survival of NB4 APL cells in cooperation with RA; that interferons alone have minimal maturation effect on NB4 cells; and, finally, that interferon gamma, but not alpha or beta, induces maturation and growth suppression of NB4 cells with de novo retinoid resistance, and partially restores RA response.
Sujet(s)
Régulation de l'expression des gènes dans la leucémie/effets des médicaments et des substances chimiques , Interféron alpha/pharmacologie , Leucémie aiguë promyélocytaire/anatomopathologie , Leucocytes/effets des médicaments et des substances chimiques , Protéines tumorales/biosynthèse , Cellules souches tumorales/effets des médicaments et des substances chimiques , Protéines nucléaires , Protéines de fusion oncogènes/biosynthèse , Facteurs de transcription/biosynthèse , Trétinoïne/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Division cellulaire/effets des médicaments et des substances chimiques , Chromosomes humains de la paire 15/génétique , Chromosomes humains de la paire 15/ultrastructure , Chromosomes humains de la paire 17/génétique , Chromosomes humains de la paire 17/ultrastructure , Résistance aux médicaments antinéoplasiques/génétique , Humains , Interféron alpha-2 , Interféron gamma/pharmacologie , Leucémie aiguë promyélocytaire/génétique , Leucocytes/métabolisme , Protéines tumorales/génétique , Cellules souches tumorales/métabolisme , Cellules souches tumorales/anatomopathologie , Protéines de fusion oncogènes/génétique , Protéine de la leucémie promyélocytaire , Protéines recombinantes , Facteurs de transcription/génétique , Translocation génétique , Cellules cancéreuses en culture , Protéines suppresseurs de tumeursRÉSUMÉ
In a selected set of 44 high-resolution, non-homologous protein structures, the intramolecular hydrogen bonds or salt bridges formed by ionizable amino acid side chains were identified and analyzed. The analysis was based on the investigation of several properties of the involved residues such as their solvent exposure, their belonging to a certain secondary structural element, and their position relative to the N- and C-termini of their respective structural element. It was observed that two-thirds of the interactions made by basic or acidic side chains are hydrogen bonds to polar uncharged groups. In particular, the majority (78%) of the hydrogen bonds between ionizable side chains and main chain polar groups (sch:mch bonds) involved at least one buried atom, and in 42% of the cases both interacting atoms were buried. In alpha-helices, the sch:mch bonds observed in the proximity of the C- and N-termini show a clear preference for acidic and basic side chains, respectively. This appears to be due to the partial charges of peptide group atoms at the termini of alpha-helices, which establish energetically favorable electrostatic interactions with side chain carrying opposite charge, at distances even greater than 4.5 angstrom. The sch:mch interactions involving ionizable side chains that belong either to beta-strands or to the central part of alpha-helices are based almost exclusively on basic residues. This results from the presence of main chain carbonyl oxygen atoms in the protein core which have unsatisfied hydrogen bonding capabilities.
Sujet(s)
Structure secondaire des protéines , Liaison hydrogène , Ions , Sels/composition chimiqueRÉSUMÉ
Clinicobiological, histological, cytogenetic and molecular genetic studies were performed in a case of atypical B-cell chronic lymphocytic leukaemia (B-CLL) with the t(11;14)(q13;q32) evolving into Richter's syndrome (RS) in order (a) to determine the clonal relationship between the cell of origin for B-CLL and RS, and (b) to analyse genetic events underlying the disease progression in this patient. After 4 years following diagnosis, a rapid deterioration of the clinical picture occurred, concomitant with the appearance of large lymphoid blasts in peripheral blood (PB), bone marrow (BM) and ascites samples. A diagnosis of RS was made and cytogenetic analysis revealed karyotype evolution with trisomy 7 and del(17p) in addition to t(11;14). Fluorescence in situ hybridization showed 78% lymphoid blast cells obtained from ascites sample to be trisomic using a chromosome-7-specific pericentromeric probe. Whereas no rearrangement of the c-myc proto-oncogene was detected at disease progression, direct sequencing of p53 gene exon 5-9 revealed an exon 7 missense point mutation. This abnormality was not present in the CLL phase. Immunological staining with the monoclonal antibody PAb-1801, detecting the p53 protein product, revealed a negative pattern in the CLL phase, whereas 24% positivity was documented in representative samples obtained at RS. It is concluded that RS was cytogenetically related with B-CLL in this patient, suggesting the occurrence of a bona fide transformation and that the mutation of p53 exon 7, in association with the development of 17p deletion, possibly played a role in the development of RS.
Sujet(s)
Gènes p53 , Leucémie B/génétique , Lymphome B diffus à grandes cellules/génétique , Translocation génétique , Sujet âgé , Séquence nucléotidique , Chromosomes humains de la paire 11 , Chromosomes humains de la paire 14 , Amorces ADN/génétique , Exons , Femelle , Délétion de gène , Humains , Leucémie B/immunologie , Lymphome B diffus à grandes cellules/immunologie , Données de séquences moléculaires , Mutation ponctuelle , Réaction de polymérisation en chaîne , Proto-oncogène Mas , TrisomieRÉSUMÉ
Although p53 mutations have been described frequently in high-grade B-cell non-Hodgkin's lymphoma (NHL), they have only been reported occasionally in low-grade NHL. We therefore describe clincobiologic and molecular genetic findings in two patients with p53 mutations and leukemic mantle cell lymphoma featuring an unusually aggressive course. Circulating malignant cells showed irregularity of nuclear outline with frequent deep clefts in both cases. Immunologic studies of neoplastic cells from peripheral blood samples and from cells obtained from an involved lymph node showed a mantle B-cell phenotype (CD5+, CD19+, CD22+, CD23- or weakly+ and bright expression for surface immunoglobulins). Malignant cells were shown to be hyperdiploid by cytofluorimetric study of DNA content and the presence of the t(11;14)(q13q32) was documented in one case. An altered electrophoretic mobility of p53 exon 5 was seen in both cases, with a missense mutation at codon 158 present in one case and a CAG to TAG mutation resulting in a 167-stop codon present in the second case. The percent of reactive cells with the 1801 monoclonal antibody detecting an epitope of the p53 was 37% in one case and 1% in the second case, supporting the notion that immunologic overexpression cannot be used for a selection criterion for the detection of p53 mutations. From these findings and from data available in the literature the conclusion can be drawn that p53 gene mutations at codons 158 and 167 may be associated with lymphoproliferative disorders and that low- or intermediate-grade NHL, including leukemic mantle cell lymphoma, may frequently carry this genetic change.